Conditional overexpression of active transforming growth factor β1 in vivo accelerates metastases of transgenic mammary tumors

Cancer Research

Volumn 64, Issue 24, 2004, Pages 9002-9011

  Muraoka Cook, Rebecca S ^a   Kurokawa, Hirokazu ^a,f   Koh, Yasuhiro ^a   Forbes, James T ^a   Roebuck, L Renee ^a   Barcellos Hoff, Mary Helen ^e   Moody, Susan E ^c,d   Chodosh, Lewis A ^c,d   Arteaga, Carlos L ^a,b  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT INGRAM CANCER CENTER   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d UNIVERSITY OF PENNSYLVANIA   (United States)

^e LAWRENCE BERKELEY NATIONAL LABORATORY   (United States)

^f AKITA RED CROSS HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOXYCYCLINE; NUCLEAR PROTEIN; SMAD2 PROTEIN; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1; VIRUS MIDDLE T ANTIGEN;

ANCHORAGE INDEPENDENT GROWTH; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BREAST TUMOR; CANCER GROWTH; CARCINOGENICITY; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; FEMALE; GENE ACTIVATION; GENE INDUCTION; GENE OVEREXPRESSION; IN VIVO STUDY; LUNG METASTASIS; MALIGNANT TRANSFORMATION; METASTASIS; MOUSE; NONHUMAN; POLYOMA VIRUS; PRIORITY JOURNAL; PROTEIN INDUCTION; TRANSGENIC MOUSE; TUMOR CELL; TUMOR VOLUME;

ANIMALS; CELL MOVEMENT; DNA, ANTISENSE; DNA-BINDING PROTEINS; FEMALE; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, TRANSGENIC; NEOPLASM METASTASIS; ONCOGENES; SMAD PROTEINS; TRANS-ACTIVATORS; TRANSFORMING GROWTH FACTOR BETA; TRANSFORMING GROWTH FACTOR BETA1;

EID: 10844224603     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-04-2111     Document Type: Article

References (62)

1. Massague J. TGF-β signal transduction. Annu Rev Biochem 1998;67:753-91.
2. Massague J, Chen YG. Controlling TGF-β signaling. Genes Dev 2000;14:627-44.
3. Wrana JL, Attisano L, Wieser R, Ventura F, Massague J. Mechanism of activation of the TGF-β receptor. Nature 1994;370:341-7.
4. Derynck R, Zhang YE. Smad-dependent and Smad-independent pathways in TGF-β family signalling. Nature 2003;425:577-84.
5. Wakefield LM, Roberts AB. TGF-β signaling: positive and negative effects on tumorigenesis. Curr Opin Genet Dev 2002;12:22-9.
6. Engle SJ, Moving JB, Boivin GP, Ormsby I, Gartside PS, Doetschman T. Transforming growth factor β1 suppresses nonmetastatic colon cancer at an early stage of tumorigenesis. Cancer Res 1999;59:3379-86.
7. Glick AB, Weinberg WC, Wu IH, Quan W, Yuspa SH. Transforming growth factor β 1 suppresses genomic instability independent of a G1 arrest, p53, and Rb. Cancer Res 1996;56:3645-50.
8. Kordon EC, McKnight RA, Jhappan C, Hennighausen L, Merlino G, Smith GH. Ectopic TGF β 1 expression in the secretory mammary epithelium induces early senescence of the epithelial stem cell population. Dev Biol 1995;168:47-61.
9. Pierce DF Jr, Gorska AE, Chytil A, et al. Mammary tumor suppression by transforming growth factor β 1 transgene expression. Proc Natl Acad Sci USA 1995;92:4254-8.
10. Cui W, Fowlis DJ, Bryson S, et al. TGFβ1 inhibits the formation of benign skin tumors, but enhances progression to invasive spindle carcinomas in transgenic mice. Cell 1996;86:531-42.
11. Zhu Y, Richardson JA, Parada LF, Graff JM. Smad3 mutant mice develop metastatic colorectal cancer. Cell 1998;94:703-14.
12. Xu X, Brodie SG, Yang X, et al. Haploid loss of the tumor suppressor Smad4/Dpc4 initiates gastric polyposis and cancer in mice. Oncogene 2000;19:1868-74.
13. Gorska AE, Joseph H, Derynck R, Moses HL, Serra R. Dominant-negative interference of the transforming growth factor β type II receptor in mammary gland epithelium results in alveolar hyperplasia and differentiation in virgin mice. Cell Growth Differ 1998;9:229-38.
14. Bottinger EP, Jakubczak JL, Haines DC, Bagnall K, Wakefield LM. Transgenic mice overexpressing a dominant-negative mutant type II transforming growth factor β receptor show enhanced tumorigenesis in the mammary gland and lung in response to the carcinogen 7,12-dimethylbenz-[a]-anthracene. Cancer Res 1997;57:5564-70.
15. Go C, Li P, Wang XJ. Blocking transforming growth factor β signaling in transgenic epidermis accelerates chemical carcinogenesis: a mechanism associated with increased angiogenesis. Cancer Res 1999;59:2861-8.
16. Gorska AE, Jensen RA, Shyr Y, Aakre ME, Bhowmick NA, Moses HL. Transgenic mice expressing a dominant-negative mutant type II transforming growth factor-β receptor exhibit impaired mammary development and enhanced mammary tumor formation. Am J Pathol 2003;163:1539-49.
17. Markowitz S, Wang J, Myeroff L, et al. Inactivation of the type II TGF-β receptor in colon cancer cells with microsatellite instability. Science 1995;268:1336-8.
18. Wang J, Sun L, Myeroff L, et al. Demonstration that mutation of the type II transforming growth factor β receptor inactivates its tumor suppressor activity in replication error-positive colon carcinoma cells. J Biol Chem 1995;270:22044-9.
19. Derynck R, Akhurst RJ, Balmain A. TGF-β signaling in tumor suppression and cancer progression. Nat Genet 2001;29:117-29.
20. Siegel PM, Massague J. Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer. Nat Rev Cancer 2003;3:807-20.
21. Wojtowicz-Praga S. Reversal of tumor-induced immunosuppression with TGF-β inhibitors. Invest New Drugs 2003;21:1-12.
22. Dumont N, Arteaga CL. Transforming growth factor-β and breast cancer: tumor promoting effects of transforming growth factor-β. Breast Cancer Res 2000;2:125-32.
23. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. J Cell Biol 1994;127:2021-36.
24. Oft M, Peli J, Rudaz C, Schwarz H, Beug H, Reichmann E. TGF-β1 and Ha-Ras collaborate in modulating the phenotypic plasticity and invasiveness of epithelial tumor cells. Genes Dev 1996;10:2462-77.
25. Oft M, Heider KH, Beug H. TGFβ signaling is necessary for carcinoma cell invasiveness and metastasis. Curr Biol 1998;8:1243-52.
26. Weeks BH, He W, Olson KL, Wang XJ. Inducible expression of transforming growth factor β1 in papillomas causes rapid metastasis. Cancer Res 2001;61:7435-43.
27. Oft M, Akhurst RJ, Balmain A. Metastasis is driven by sequential elevation of H-ras and Smad2 levels. Nat Cell Biol 2002;4:487-94.
28. Dumont N, Arteaga CL. Targeting the TGF β signaling network in human neoplasia. Cancer Cell 2003;3:531-6.
29. Siegel PM, Shu W, Cardiff RD, Muller WJ, Massague J. Transforming growth factor β signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. Proc Natl Acad Sci USA 2003;100:8430-5.
30. Muraoka RS, Koh Y, Roebuck LR, et al. Increased malignancy of Neu-induced mammary tumors overexpressing active transforming growth factor β1. Mol Cell Biol 2003;23:8691-703.
31. Watanabe T, Wu TT, Catalane PJ, et al. Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 2001;344:1196-206.
32. Guy CT, Cardiff RD, Muller WJ. Induction of mammary tumors by expression of polyomavirus middle T oncogene: a transgenic mouse model for metastatic disease. Mol Cell Biol 1992;12:954-61.
33. Wu RS, Kobie JJ, Besselsen DG, et al. Comparative analysis of IFN-γ B7.1 and antisense TGF-β gene transfer on the tumorigenicity of a poorly immunogenic metastatic mammary carcinoma. Cancer Immunol Immunother 2001;50:229-40.
34. Muraoka RS, Lenferink AE, Simpson J, et al. Cyclin-dependent kinase inhibitor p27(Kip1) is required for mouse mammary gland morphogenesis and function. J Cell Biol 2001;153:917-32.
35. Lenferink AE, Simpson JF, Shawver LK, Coffey RJ, Forbes JT, Arteaga CL. Blockade of the epidermal growth factor receptor tyrosine kinase suppresses tumorigenesis in MMTV/Neu + MMTV/TGF-α bigenic mice. Proc Natl Acad Sci USA 2000;97:9609-14.
36. Muraoka RS, Lenferink AE, Law B, et al. ErbB2/Neu-induced, cyclin D1-dependent transformation is accelerated in p27-haploinsufficient mammary epithelial cells but impaired in p27-null cells. Mol Cell Biol 2002;22:2204-19.
37. Ehrhart EJ, Segarini P, Tsang ML, Carroll AG, Barcellos-Hoff MH. Latent transforming growth factor β1 activation in situ: quantitative and functional evidence after low-dose γ-irradiation. FASEB J 1997;11:991-1002.
38. Pierce DF Jr, Johnson MD, Matsui Y, et al. Inhibition of mammary duct development but not alveolar outgrowth during pregnancy in transgenic mice expressing active TGF-β1. Genes Dev 1993;7:2308-17.
39. Gunther EJ, Belka GK, Wertheim GB, et al. A novel doxycycline-inducible system for the transgenic analysis of mammary gland biology. FASEB J 2002;16:283-92.
40. Tang B, Bottinger EP, Jakowlew SB, et al. Transforming growth factor-β1 is a new form of tumor suppressor with true haploid insufficiency. Nat Med 1998;4:802-7.
41. Ziv E, Cauley J, Morin PA, Saiz R, Browner WS. Association between the T29->C polymorphism in the transforming growth factor β1 gene and breast cancer among elderly white women: The Study of Osteoporotic Fractures. JAMA 2001;285:2859-63.
42. Lin HY, Moustakas A, Knaus P, Wells RG, Henis YI, Lodish HF. The soluble exoplasmic domain of the type II transforming growth factor (TGF)-β receptor. A heterogeneously glycosylated protein with high affinity and selectivity for TGF-β ligands. J Biol Chem 1995;270:2747-54.
43. Muraoka RS, Dumont N, Ritter CA, et al. Blockade of TGF-β inhibits mammary tumor cell viability, migration, and metastases. J Clin Investig 2002;109:1551-9.
44. Webster MA, Hutchinson JN, Rauh MJ, et al. Requirement for both Shc and phosphatidylinositol 3′ kinase signaling pathways in polyomavirus middle T-mediated mammary tumorigenesis. Mol Cell Biol 1998;18:2344-59.
45. Ito N, Kawata S, Tamura S, et al. Positive correlation of plasma transforming growth factor-β 1 levels with tumor vascularity in hepatocellular carcinoma. Cancer Lett 1995;89:45-8.
46. Shariat SF, Kim JH, Andrews B, et al. Preoperative plasma levels of transforming growth factor β(1) strongly predict clinical outcome in patients with bladder carcinoma. Cancer 2001;92:2985-92.
47. Shariat SF, Shalev M, Menesses-Diaz A, et al. Preoperative plasma levels of transforming growth factor β(1) (TGF-β(1)) strongly predict progression in patients undergoing radical prostatectomy. J Clin Oncol 2001;19:2856-64.
48. Tsushima H, Ito N, Tamura S, et al. Circulating transforming growth factor β 1 as a predictor of liver metastasis after resection in colorectal cancer. Clin Cancer Res 2001;7:1258-62.
49. Anscher MS, Peters WP, Reisenbichler H, Petros WP, Jirtle RL. Transforming growth factor β as a predictor of liver and lung fibrosis after autologous bone marrow transplantation for advanced breast cancer. N Engl J Med 1993;328:1592-8.
50. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. Plasma transforming growth factor-β1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 1999;86:1712-9.
51. Anscher MS, Kong FM, Murase T, Jirtle RL. Short communication: normal tissue injury after cancer therapy is a local response exacerbated by an endocrine effect of TGF β. Br J Radiol 1995;68:331-3.
52. Keyes KA, Mann L, Cox K, et al. Circulating angiogenic growth factor levels in mice bearing human tumors using Luminex Multiplex technology. Cancer Chemother Pharmacol 2003;51:321-7.
53. Keyes K, Cox K, Treadway P, et al. An in vitro tumor model: analysis of angiogenic factor expression after chemotherapy. Cancer Res 2002;62:5597-602.
54. Kakeji Y, Maehara Y, Ikebe M, Teicher BA. Dynamics of tumor oxygenation, CD31 staining and transforming growth factor-β levels after treatment with radiation or cyclophosphamide in the rat 13762 mammary carcinoma. Int J Radiat Oncol Biol Phys 1997;37:1115-23.
55. Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-β activation in irradiated murine mammary gland. J Clin Investig 1994;93:892-9.
56. Shin I, Bakin AV, Rodeck U, Brunei A, Arteaga CL. Transforming growth factor β enhances epithelial cell survival via Akt-dependent regulation of FKHRL1. Mol Biol Cell 2001;12:3328-39.
57. Janda E, Lehmann K, Killisch I, et al. Ras and TGF[β] cooperatively regulate epithelial cell plasticity and metastasis: dissection of Ras signaling pathways. J Cell Biol 2002;156:299-313.
58. Belizario JE, Dinarello CA. Interleukin 1, interleukin 6, tumor necrosis factor, and transforming growth factor β increase cell resistance to tumor necrosis factor cytotoxicity by growth arrest in the G1 phase of the cell cycle. Cancer Res 1991;51:2379-85.
59. McCormack ES, Borzillo GV, Ambrosino C, et al. Transforming growth factor-β3 protection of epithelial cells from cycle-selective chemotherapy in vitro. Biochem Pharmacol 1997;53:1149-59.
60. Liu P, Menon K, Alvarez E, Lu K, Teicher BA. Transforming growth factor-β and response to anticancer therapies in human liver and gastric tumors in vitro and in vivo. Int J Oncol 2000;16:599-610.
61. Teicher BA, Kakeji Y, Ara G, Herbst RS, Northey D. Prostate carcinoma response to cytotoxic therapy: in vivo resistance. In Vivo 1997;11:453-61.
62. Teicher BA, Ikebe M, Ara G, Keyes SR, Herbst RS. Transforming growth factor-β 1 overexpression produces drug resistance in vivo: reversal by decorin. In Vivo 1997;11:463-72.